Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00718523 · ClinicalTrials.gov registry record · Phase 2
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Phase 2 study, sponsored by Translational Research in Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT00718523 is a Phase 2 study that was terminated before completion, run by Translational Research in Oncology. The registered enrollment target is 170 participants.
The verdict
NCT00718523, a Phase 2 study, was terminated before completion, sponsored by Translational Research in Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (\<1 cm) FIGO stage III and IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.
Interventions
- DRUG AMG 479
- DRUG AMG 479 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00718523
The ClinicalTrials.gov registry entry for NCT00718523 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Research in Oncology, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AMG 479 is the first listed.
NCT00718523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00718523 about?
NCT00718523 is a clinical study titled "Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer". This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (\<1 cm) FIGO stage III and IV (positive pleural cytology only) ovarian epithelial (including fallopian tub...
What is the current status of trial NCT00718523?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2009-01. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00718523?
The interventions under investigation include: AMG 479 (DRUG), AMG 479 Placebo (DRUG).
Who is sponsoring clinical trial NCT00718523?
This trial is sponsored by Translational Research in Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.